The AACE update to its 2026 algorithm for the management of type 2 diabetes includes a new section on diabetes classification ...

Eli Lilly disclosed that retatrutide, its experimental triple hormone receptor agonist, hit the primary and all key secondary ...

India is home to nearly 90 million people with T2DM , with an estimated 39.4 million remaining undiagnosed. Recent estimates ...

CKD was present in ~26% of adults with type 1 diabetes, yet only ~11% of those with CKD received CKM therapy, indicating ...

Biomea Fusion, Inc. (“Biomea,” “Biomea Fusion,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that Juan Pablo Frías, MD, delivered an oral ...

Finland: Researchers have discovered in new research that young children with acute wheezing showed greater clinically ...

Should A1c remain the gold standard for routine monitoring of glucose control in people with diabetes, or is it time to shift ...

The first-in-class injectable could be the next big thing in diabetes and obesity treatment.

Off-label adjunctive use requires careful dosing, dose adjustments of insulin and other medications, and close monitoring.

Bayer announces finerenone meets primary endpoint in pivotal phase III FIND-CKD study in patients with non-diabetic chronic kidney disease: Berlin Tuesday, March 17, 2026, 15:00 H ...

Topline results were announced from a phase 3 trial evaluating retatrutide in patients with type 2 diabetes (T2D).